Advanced search
1 file | 943.69 KB

EGFR in melanoma : clinical significance and potential therapeutic target

Barbara Boone (UGent) , Koen Jacobs, Liesbeth Ferdinande (UGent) , Jasmien Taildeman (UGent) , Jo Lambert (UGent) , Marc Peeters (UGent) , Marc Bracke (UGent) , Patrick Pauwels (UGent) and Lieve Brochez (UGent)
(2011) JOURNAL OF CUTANEOUS PATHOLOGY. 38(6). p.492-502
Author
Organization
Abstract
Background: The role of epidermal growth factor receptor (EGFR) has been established in a range of neoplasms. In melanoma, data on EGFR protein expression are conflicting. Fluorescence in situ hybridization ( FISH) analysis for EGFR gene expression in melanoma showed EGFR gene amplification to be linked with worse prognosis. Cetuximab has been shown to suppress the formation of metastasis in Methods: EGFR protein expression and gene copy number status were evaluated by means of immunohistochemistry and FISH in melanoma samples of patients with known clinicopathological data. Associations between EGFR expression and prognostic parameters were investigated. The effect of different cetuximab concentrations on the BLM melanoma cell line was evaluated by means of methyl tetrazolium (MTT), sulforhodamine B (SRB) and Matrigel invasion assays. Results: EGFR protein expression was more frequently observed in patients with a positive sentinel lymph node. However, EGFR immunostaining has no predictive value. The presence of EGFR polysomy was associated with thicker tumors. Treatment of the BLM melanoma cell line with different concentrations of cetuximab reduced the invasive capacity of the cells, but did not alter cell viability or growth. Conclusion: EGFR appears to be involved in progression and metastasis of a subset of melanomas. Targeting EGFR could therefore represent a therapeutic option for these melanomas.
Keywords
cancer research, dermatopathology, malignant melanoma, GROWTH-FACTOR RECEPTOR, CELL LUNG-CANCER, METASTATIC MELANOMA, MALIGNANT MELANOMAS, CUTANEOUS MELANOMA, POOR-PROGNOSIS, EXPRESSION, GENE, MELANOCYTES, PROGRESSION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 943.69 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Boone, Barbara, Koen Jacobs, Liesbeth Ferdinande, Jasmien Taildeman, Jo Lambert, Marc Peeters, Marc Bracke, Patrick Pauwels, and Lieve Brochez. 2011. “EGFR in Melanoma : Clinical Significance and Potential Therapeutic Target.” Journal of Cutaneous Pathology 38 (6): 492–502.
APA
Boone, Barbara, Jacobs, K., Ferdinande, L., Taildeman, J., Lambert, J., Peeters, M., Bracke, M., et al. (2011). EGFR in melanoma : clinical significance and potential therapeutic target. JOURNAL OF CUTANEOUS PATHOLOGY, 38(6), 492–502.
Vancouver
1.
Boone B, Jacobs K, Ferdinande L, Taildeman J, Lambert J, Peeters M, et al. EGFR in melanoma : clinical significance and potential therapeutic target. JOURNAL OF CUTANEOUS PATHOLOGY. 2011;38(6):492–502.
MLA
Boone, Barbara, Koen Jacobs, Liesbeth Ferdinande, et al. “EGFR in Melanoma : Clinical Significance and Potential Therapeutic Target.” JOURNAL OF CUTANEOUS PATHOLOGY 38.6 (2011): 492–502. Print.
@article{1210949,
  abstract     = {Background: The role of epidermal growth factor receptor (EGFR) has been established in a range of neoplasms. In melanoma, data on EGFR protein expression are conflicting. Fluorescence in situ hybridization ( FISH) analysis for EGFR gene expression in melanoma showed EGFR gene amplification to be linked with worse prognosis. Cetuximab has been shown to suppress the formation of metastasis in 
Methods: EGFR protein expression and gene copy number status were evaluated by means of immunohistochemistry and FISH in melanoma samples of patients with known clinicopathological data. Associations between EGFR expression and prognostic parameters were investigated. The effect of different cetuximab concentrations on the BLM melanoma cell line was evaluated by means of methyl tetrazolium (MTT), sulforhodamine B (SRB) and Matrigel invasion assays. 
Results: EGFR protein expression was more frequently observed in patients with a positive sentinel lymph node. However, EGFR immunostaining has no predictive value. The presence of EGFR polysomy was associated with thicker tumors. Treatment of the BLM melanoma cell line with different concentrations of cetuximab reduced the invasive capacity of the cells, but did not alter cell viability or growth. 
Conclusion: EGFR appears to be involved in progression and metastasis of a subset of melanomas. Targeting EGFR could therefore represent a therapeutic option for these melanomas.},
  author       = {Boone, Barbara and Jacobs, Koen and Ferdinande, Liesbeth and Taildeman, Jasmien and Lambert, Jo and Peeters, Marc and Bracke, Marc and Pauwels, Patrick and Brochez, Lieve},
  issn         = {0303-6987},
  journal      = {JOURNAL OF CUTANEOUS PATHOLOGY},
  keyword      = {cancer research,dermatopathology,malignant melanoma,GROWTH-FACTOR RECEPTOR,CELL LUNG-CANCER,METASTATIC MELANOMA,MALIGNANT MELANOMAS,CUTANEOUS MELANOMA,POOR-PROGNOSIS,EXPRESSION,GENE,MELANOCYTES,PROGRESSION},
  language     = {eng},
  number       = {6},
  pages        = {492--502},
  title        = {EGFR in melanoma : clinical significance and potential therapeutic target},
  url          = {http://dx.doi.org/10.1111/j.1600-0560.2011.01673.x},
  volume       = {38},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: